BioCentury
ARTICLE | Clinical News

Genmab slides as Darzalex combo trials discontinued

May 29, 2018 5:12 AM UTC

Genmab A/S (CSE:GEN; Pink:GMXAY) sank DKK239.30 (20%) to DKK953.20 in Copenhagen on Monday after it said partner Janssen Biotech Inc. will discontinue two studies of Darzalex daratumumab in combination with different immune checkpoint inhibitors.

The studies include the Phase Ib/II CALLISTO/LUC2001 trial, which is evaluating Darzalex plus PD-L1 inhibitor Tecentriq atezolizumab to treat non-small cell lung cancer (NSCLC); and the Phase I MMY2036 trial of Darzalex plus JNJ-63723283, an anti-PD-1 mAb, to treat multiple myeloma...